Allosteric Modulation of Ionotropic Glutamate Receptors: An Outlook on New Therapeutic Approaches To Treat Central Nervous System Disorders

Overview

Journal ACS Med Chem Lett

Publisher American Chemical Society

Specialty Chemistry

Date 2019 Mar 21

PMID 30891118

Citations 13

Authors

Simone Brogi

Giuseppe Campiani

Margherita Brindisi

Stefania Butini

Affiliations

Soon will be listed here.

Abstract

The allosteric targeting of ionotropic glutamate receptors (iGluRs) is a valuable approach for treating various central nervous system (CNS) disorders. In this frame, this Innovations provides a summary of the state-of-the art in the development of allosteric modulators for iGluRs and offers an outlook regarding innovative strategies for treating neurological diseases.

Citing Articles

Amplification of the therapeutic potential of AMPA receptor potentiators from the nootropic era to today.

Radin D, Lippa A, Rana S, Fuller D, Smith J, Cerne R Pharmacol Biochem Behav. 2025; 248:173967.

PMID: 39894310 PMC: 11849398. DOI: 10.1016/j.pbb.2025.173967.

New Chemo-, Regio- and Stereoselective Reactions and Methods in Organic Synthesis.

Musalov M Int J Mol Sci. 2025; 25(24.

PMID: 39769175 PMC: 11676199. DOI: 10.3390/ijms252413409.

Aberrant glutamatergic systems underlying impulsive behaviors: Insights from clinical and preclinical research.

Yates J Prog Neuropsychopharmacol Biol Psychiatry. 2024; 135:111107.

PMID: 39098647 PMC: 11409449. DOI: 10.1016/j.pnpbp.2024.111107.

Roles of AMPA receptors in social behaviors.

Xu Q, Larosa A, Wong T Front Synaptic Neurosci. 2024; 16:1405510.

PMID: 39056071 PMC: 11269240. DOI: 10.3389/fnsyn.2024.1405510.

Dalzanemdor (SAGE-718), a novel, investigational N-methyl-D-aspartate receptor positive allosteric modulator: Safety, tolerability, and clinical pharmacology in randomized dose-finding studies in healthy participants and an open-label study in....

Koenig A, Lewis M, Wald J, Li S, Varoglu M, Dai J Clin Transl Sci. 2024; 17(7):e13852.

PMID: 38988035 PMC: 11236904. DOI: 10.1111/cts.13852.

References

Ruel J, Bobbin R, Vidal D, Pujol R, Puel J . The selective AMPA receptor antagonist GYKI 53784 blocks action potential generation and excitotoxicity in the guinea pig cochlea. Neuropharmacology. 2000; 39(11):1959-73. DOI: 10.1016/s0028-3908(00)00069-1. View

Belayev L, Alonso O, Liu Y, Chappell A, Zhao W, Ginsberg M . Talampanel, a novel noncompetitive AMPA antagonist, is neuroprotective after traumatic brain injury in rats. J Neurotrauma. 2001; 18(10):1031-8. DOI: 10.1089/08977150152693728. View

Lazzaro J, Paternain A, Lerma J, Chenard B, Ewing F, Huang J . Functional characterization of CP-465,022, a selective, noncompetitive AMPA receptor antagonist. Neuropharmacology. 2002; 42(2):143-53. DOI: 10.1016/s0028-3908(01)00170-8. View

ONeill M, Murray T, Clay M, Lindstrom T, Yang C, Nisenbaum E . LY503430: pharmacology, pharmacokinetics, and effects in rodent models of Parkinson's disease. CNS Drug Rev. 2005; 11(1):77-96. PMC: 6741716. DOI: 10.1111/j.1527-3458.2005.tb00037.x. View

Kobayashi T, Washiyama K, Ikeda K . Inhibition of G protein-activated inwardly rectifying K+ channels by ifenprodil. Neuropsychopharmacology. 2005; 31(3):516-24. DOI: 10.1038/sj.npp.1300844. View

Balannik V, Menniti F, Paternain A, Lerma J, Stern-Bach Y . Molecular mechanism of AMPA receptor noncompetitive antagonism. Neuron. 2005; 48(2):279-88. DOI: 10.1016/j.neuron.2005.09.024. View

Moriguchi S, Shioda N, Maejima H, Zhao X, Marszalec W, Yeh J . Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor. Mol Pharmacol. 2006; 71(2):580-7. DOI: 10.1124/mol.106.027607. View

Woolley M, Waters K, Gartlon J, Lacroix L, Jennings C, Shaughnessy F . Evaluation of the pro-cognitive effects of the AMPA receptor positive modulator, 5-(1-piperidinylcarbonyl)-2,1,3-benzoxadiazole (CX691), in the rat. Psychopharmacology (Berl). 2008; 202(1-3):343-54. DOI: 10.1007/s00213-008-1325-2. View

Yang C, Svensson K . Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia. Pharmacol Ther. 2008; 120(3):317-32. DOI: 10.1016/j.pharmthera.2008.08.004. View

10.

Hampson R, Espana R, ROGERS G, Porrino L, Deadwyler S . Mechanisms underlying cognitive enhancement and reversal of cognitive deficits in nonhuman primates by the ampakine CX717. Psychopharmacology (Berl). 2008; 202(1-3):355-69. PMC: 3107999. DOI: 10.1007/s00213-008-1360-z. View

11.

Mony L, Kew J, Gunthorpe M, Paoletti P . Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential. Br J Pharmacol. 2009; 157(8):1301-17. PMC: 2765303. DOI: 10.1111/j.1476-5381.2009.00304.x. View

12.

Ptak C, Ahmed A, Oswald R . Probing the allosteric modulator binding site of GluR2 with thiazide derivatives. Biochemistry. 2009; 48(36):8594-602. PMC: 2756660. DOI: 10.1021/bi901127s. View

13.

Carter C, Lloyd K, Zivkovic B, Scatton B . Ifenprodil and SL 82.0715 as cerebral antiischemic agents. III. Evidence for antagonistic effects at the polyamine modulatory site within the N-methyl-D-aspartate receptor complex. J Pharmacol Exp Ther. 1990; 253(2):475-82. View

14.

Francotte P, Goffin E, Fraikin P, Lestage P, Van Heugen J, Gillotin F . New fluorinated 1,2,4-benzothiadiazine 1,1-dioxides: discovery of an orally active cognitive enhancer acting through potentiation of the 2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic acid receptors. J Med Chem. 2010; 53(4):1700-11. DOI: 10.1021/jm901495t. View

15.

Ward S, Harries M, Aldegheri L, Andreotti D, Ballantine S, Bax B . Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator. J Med Chem. 2010; 53(15):5801-12. DOI: 10.1021/jm1005429. View

16.

Traynelis S, Wollmuth L, McBain C, Menniti F, Vance K, Ogden K . Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev. 2010; 62(3):405-96. PMC: 2964903. DOI: 10.1124/pr.109.002451. View

17.

Costa B, Irvine M, Fang G, Eaves R, Mayo-Martin M, Skifter D . A novel family of negative and positive allosteric modulators of NMDA receptors. J Pharmacol Exp Ther. 2010; 335(3):614-21. PMC: 2993558. DOI: 10.1124/jpet.110.174144. View

18.

Arias H . Positive and negative modulation of nicotinic receptors. Adv Protein Chem Struct Biol. 2010; 80:153-203. DOI: 10.1016/B978-0-12-381264-3.00005-9. View

19.

Zhou H, Chen S, Pan H . Targeting N-methyl-D-aspartate receptors for treatment of neuropathic pain. Expert Rev Clin Pharmacol. 2011; 4(3):379-88. PMC: 3113704. DOI: 10.1586/ecp.11.17. View

20.

Rogawski M . Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr. 2011; 11(2):56-63. PMC: 3117497. DOI: 10.5698/1535-7511-11.2.56. View